🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Morphosys to slash early drug research programmes to preserve cash

Published 02/03/2023, 09:08
Updated 02/03/2023, 09:10
© Reuters.

FRANKFURT (Reuters) - German biotech firm Morphosys said it would stop its work on drug candidates that have not yet been tested on humans after its 2023 revenue prospects worsened.

In a statement on Thursday, Morphosys added it would reduce its workforce at the company’s headquarters in Planegg, Germany, by approximately 17% as a result of the cutback.

Morphosys in January lowered its 2023 sales target for its most important drug, Monjuvi against a certain type of lymphoma, raising concerns among analysts about its ability to fund its research and development activities.

Its shares plunged in November after Roche's Alzheimer's drug candidate, in which Morphosys held certain rights, failed to slow dementia progression in key trials.

"Given the challenging market we are operating in, we need to continue to concentrate our investments on our most-advanced clinical programs that will have the greatest and most immediate impact on patients’ lives,” said Chief Executive Officer Jean-Paul Kress.

Morphosys added it would explore other options for its pre-clinical research programmes.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.